Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
284 hedge funds and large institutions have $8.18B invested in Sage Therapeutics in 2019 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 100 increasing their positions, 94 reducing their positions, and 31 closing their positions.
42% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 31
4% more funds holding
Funds holding: 272 → 284 (+12)
6% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 94
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0.74% less ownership
Funds ownership: 113.57% → 112.84% (-0.74%)
17% less call options, than puts
Call options by funds: $102M | Put options by funds: $124M
23% less capital invested
Capital invested by funds: $10.6B → $8.18B (-$2.46B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$86.4M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$62.5M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$44.1M |
| 4 |
CII
Capital International Inc
Los Angeles,
California
|
+$41.7M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$34.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$73.7M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$43M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$42.9M |
| 4 |
Bank of New York Mellon
New York
|
-$39.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
301
Athanor Capital
New York
| – | -$201K | -1,100 | Closed |
|
|
CAW
302
Cornerstone Advisors (Washington)
Bellevue,
Washington
| – | -$62K | -340 | Closed |
|
|
HCM
303
Highlander Capital Management
Short Hills,
New Jersey
| – | -$55K | -300 | Closed |
|
|
MRCM
304
M&R Capital Management
Summit,
New Jersey
| – | -$54K | -300 | Closed |
|
|
FPFS
305
First Personal Financial Services
Charlotte,
North Carolina
| – | -$26K | -143 | Closed |
|
|
M
306
MOTCO
San Antonio,
Texas
| – | -$19K | -102 | Closed |
|
|
DWM
307
Doyle Wealth Management
St. Petersburg,
Florida
| – | -$18K | -100 | Closed |
|
|
AC
308
Avestar Capital
New York
| – | -$17K | -98 | Closed |
|
|
PCP
309
Proficio Capital Partners
Newton,
Massachusetts
| – | -$17K | -92 | Closed |
|
310
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$2K | -12 | Closed |
|
|
GWS
311
Glassman Wealth Services
Vienna,
Virginia
| – | -$2K | -9 | Closed |
|
|
SQA
312
Simon Quick Advisors
Morristown,
New Jersey
| – | -$366 | -2 | Closed |
|
|
GT
313
Glenmede Trust
Philadelphia,
Pennsylvania
| – | +$836 | +5 | New |
|
SAGE Hedge Fund Activity: Q3 2019 in Review
284 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2019, worth a combined $8.18B — down 23% from $10.6B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new SAGE positions and 31 closed out — a net gain of 13 holders — while 100 added to existing stakes and 94 trimmed.
The largest buyer was Capital International Investors, adding an estimated $86.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $73.7M.
- 284 institutional investors held Sage Therapeutics (SAGE) as of Q3 2019, up from 272 in Q2 2019.
- Funds reported $8.18B of Sage Therapeutics stock for Q3 2019, down 23% quarter-over-quarter.
- 44 funds opened new Sage Therapeutics positions in Q3 2019 and 31 closed out, a net change of +13 holders.
- The largest Sage Therapeutics buyer in Q3 2019 was Capital International Investors, an estimated $86.4M added.
- The largest Sage Therapeutics seller in Q3 2019 was T. Rowe Price Associates, an estimated $73.7M sold.
Based on aggregated 13F filings for Q3 2019.